Engleman Heather M, McDonald James P, Graham David, Lello Glenn E, Kingshott Ruth N, Coleman Emma L, Mackay Thomas W, Douglas Neil J
Edinburgh Sleep Centre, Respiratory Medicine Unit, University of Edinburgh, Edinburgh, UK.
Am J Respir Crit Care Med. 2002 Sep 15;166(6):855-9. doi: 10.1164/rccm.2109023.
Mandibular repositioning splints (MRSs) and continuous positive airway pressure (CPAP) are used to treat the sleep apnea/hypopnea syndrome (SAHS). There are some data suggesting that patients with milder symptoms prefer MRS, but there are few comparative data on outcomes. Therefore, we performed a randomized crossover trial of 8 weeks of CPAP and 8 weeks of MRS treatment in consecutive new outpatients diagnosed with SAHS (apnea/hypopnea index [AHI] >or= 5/hour, and >or= 2 symptoms including sleepiness). Assessments at the end of both limbs comprised home sleep study, subjective ratings of treatment value, sleepiness, symptoms, and well-being, and objective tests of sleepiness and cognition. Forty-eight of 51 recruited patients completed the trial (12 women; age [mean +/- SD], 46 +/- 9 years; Epworth 14 +/- 4; median AHI, 22/hour; interquartile ratio [IQR], 11-43/hour). Significant (p <or= 0.01) differences between MRS and CPAP were observed for 7 of 21 variables (effect sizes, 0.3-0.6 SDs), all favoring CPAP, including AHI (15 +/- 16 and 8 +/- 6/hour, respectively), effectiveness rating, symptoms, Epworth (12 +/- 5 and 8 +/- 5, respectively), functional outcomes of sleepiness questionnaire, short-form 36 health survey mental component, and health transition scores. Objective sleepiness, cognitive performance, and preference for treatments were not different. In patients experiencing a mild form of the syndrome (AHI < 15, n = 18), symptoms, treatment efficacy and satisfaction, and subjective sleepiness were also better with CPAP than with MRS (effect sizes, 0.7-1.1 SDs). These results do not support these MRS devices as first-line treatment for sleepy patients with SAHS.
下颌重新定位矫治器(MRSs)和持续气道正压通气(CPAP)用于治疗睡眠呼吸暂停/低通气综合征(SAHS)。有一些数据表明症状较轻的患者更喜欢MRS,但关于治疗结果的比较数据很少。因此,我们对连续诊断为SAHS(呼吸暂停/低通气指数[AHI]≥5/小时,且有≥2种包括嗜睡在内的症状)的新门诊患者进行了一项随机交叉试验,分别进行8周的CPAP治疗和8周的MRS治疗。两个治疗阶段结束时的评估包括家庭睡眠研究、对治疗价值、嗜睡、症状和幸福感的主观评分,以及对嗜睡和认知的客观测试。51名招募患者中有48名完成了试验(12名女性;年龄[平均±标准差],46±9岁;Epworth评分14±4;AHI中位数,22/小时;四分位间距[IQR],11 - 43/小时)。在21个变量中的7个变量上观察到MRS和CPAP之间存在显著(p≤0.01)差异(效应大小,0.3 - 0.6标准差),所有这些差异均有利于CPAP,包括AHI(分别为15±16和8±6/小时)、有效性评分、症状、Epworth评分(分别为12±5和8±5)、嗜睡问卷的功能结果、简短健康调查36项精神成分以及健康转变评分。客观嗜睡、认知表现和对治疗的偏好没有差异。在患有轻度综合征形式(AHI < 15,n = 18)的患者中,CPAP在症状、治疗效果和满意度以及主观嗜睡方面也优于MRS(效应大小,0.7 - 1.1标准差)。这些结果不支持将这些MRS装置作为嗜睡SAHS患者的一线治疗方法。